French ccAFU guidelines - Update 2018-2020: Penile cancer

被引:4
|
作者
Savoie, P. -H. [1 ,2 ]
Flechon, A. [1 ,3 ]
Morel-Journel, N. [1 ,4 ]
Murez, T. [1 ,5 ]
Ferretti, L. [1 ,6 ]
Camparo, P. [1 ,7 ]
Rocher, L. [1 ,8 ]
Sebe, P. [1 ,9 ]
Mejean, A. [1 ,10 ]
机构
[1] Com Cancerol Assoc Francaise Urol, Grp Organes Genitaux Externes, Maison Urol, 11 Rue Viete, F-75017 Paris, France
[2] Hop Instruct Armees Sainte Anne, Serv Urol, BP 600, F-83800 Toulon 09, France
[3] Ctr Leon Berard, Serv Oncol Med, 28 Rue Laennec, F-69008 Lyon, France
[4] HCL Groupement Hosp Sud, Ctr Hosp Lyon Sud Pierre Benite, Serv Urol, F-69495 Pierre Benite, France
[5] CHRU Montpellier, Serv Urol, 371 Ave Doyen Gaston Giraud, F-34295 Montpellier 5, France
[6] MSP Bordeaux Bagatelle, Serv Urol, 203 Route Toulouse,BP 50048, F-33401 Talence, France
[7] Ctr pathol, 51 Rue Jeanne Arc, F-80000 Amiens, France
[8] HU Paris Sud, AP HP, Serv Radiol, Site Kremlin Bicetre, Le Kremlin Bicetre, France
[9] Grp Hosp Diaconesses Croix St Simon, Serv Urol, 125 Rue Avron, F-75020 Paris, France
[10] Univ Paris 05, Hop Europeen Georges Pompidou, AP HP, Serv Urol, F-75015 Paris, France
来源
PROGRES EN UROLOGIE | 2018年 / 28卷
关键词
Epidermoid carcinoma; Penile cancer; Inguinal adenopathy; Penectomy; Lymphadenectomy; SQUAMOUS-CELL CARCINOMA; LYMPH-NODE BIOPSY; NEOADJUVANT CHEMOTHERAPY; INGUINAL LYMPHADENECTOMY; SURGICAL-MANAGEMENT; PROGNOSTIC-FACTORS; CISPLATIN; METHOTREXATE; BLEOMYCIN; RISK;
D O I
10.1016/j.purol.2019.01.008
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Objective. - To update French oncology guidelines concerning penile cancer. Methods. - Comprehensive Medline search between 2016 and 2018 upon diagnosis, treatment and follow-up of testicular germ cell cancer to update 2016-2018 guidelines. Level of evidence was evaluated according to AGREE-II. Results. - Epidermoid carcinoma is the most common penile cancer histology. Physical examination is mandatory to define local and inguinal nodal cancer stage. MRI with artificial erection can help to assess deep infiltration in cases of organ-sparing intention. Node negative patients (defined by palpation and imaging) will present micro nodal metastases in up to 25% of cases. Invasive lymph node assessment is thus advocated except for low risk patients. Sentinel node dynamic biopsy is the first line technique. Modified bilateral inguinal lymphadenectomy is an option with higher morbidity. 18-FDG-PET is recommended in patients with palpable nodes. Chest, abdominal and pelvis computerized tomography is an option. Fine needle aspiration (when positive) is an easy way to assess inguinal palpable node pathological involvement. Treatment is mostly surgical. Free margins status is essential, but it also has to be organ-sparing when possible. Brachytherapy and topic agents can cure in selected cases. Lymph node assessment should be synchronous to the removal of the tumour when possible. Limited inguinal lymph node involvement (pN1 stage) can be cured with the only lymphadenectomy. In case of larger lymph node stage, one should consider multidisciplinary treatment including chemotherapy and inclusion in a trial. Conclusions. - Penile cancer needs demanding surgery to be cured, surrounded by chemotherapy in node positive patients. Lymph nodes involvement is a major prognostic factor. Thus, inguinal node assessment cannot be neglected. (C) 2018 Elsevier Masson SAS. All rights reserved.
引用
收藏
页码:R133 / R148
页数:16
相关论文
共 50 条
  • [1] RETRACTED: French ccAFU guidelines - Update 2018-2020: Penile cancer (Retracted Article)
    Savoie, P-H
    Flechon, A.
    Morel-Journel, N.
    Murez, T.
    Ferretti, L.
    Camparo, P.
    Rocher, L.
    Sebe, P.
    Mejean, A.
    PROGRES EN UROLOGIE, 2018, 28 (12): : S131 - S146
  • [2] French ccAFU guidelines - Update 2018-2020: Adrenal cancer
    Savoie, P. -H.
    Murez, T.
    Flechon, A.
    Sebe, P.
    Rocher, L.
    Camparo, P.
    Morel-Journel, N.
    Ferretti, L.
    Mejean, A.
    PROGRES EN UROLOGIE, 2018, 28 : R177 - R195
  • [3] French ccAFU guidelines - Update 2018-2020: Bladder cancer
    Roupret, M.
    Neuzillet, Y.
    Pignot, G.
    Comperat, E.
    Audenet, F.
    Houede, N.
    Larre, S.
    Masson-Lecomte, A.
    Colin, P.
    Brunelle, S.
    Xylinas, E.
    Roumiguie, M.
    Mejean, A.
    PROGRES EN UROLOGIE, 2018, 28 : R48 - R80
  • [4] French ccAFU guidelines - Update 2018-2020: Prostate cancer
    Rozet, F.
    Hennequin, C.
    Beauval, J. -B.
    Beuzeboc, P.
    Cormier, L.
    Fromont-Hankard, G.
    Mongiat-Artus, P.
    Ploussard, G.
    Mathieu, R.
    Brureau, L.
    Ouzzane, A.
    Azria, D.
    Brenot-Rossi, I.
    Cancel-Tassin, G.
    Cussenot, O.
    Rebillard, X.
    Lebret, T.
    Soulie, M.
    Penna, R. Renard
    Mejean, A.
    PROGRES EN UROLOGIE, 2018, 28 : R81 - R132
  • [5] French ccAFU guidelines - Update 2018-2020: Bladder cancer
    Roupret, M.
    Neuzillet, Y.
    Pignot, G.
    Comperat, E.
    Audenet, F.
    Houede, N.
    Larre, S.
    Masson-Lecomte, A.
    Colin, P.
    Brunelle, S.
    Xylinas, E.
    Roumiguie, M.
    Mejean, A.
    PROGRES EN UROLOGIE, 2018, 28 (12): : S46 - S78
  • [6] Update 2018-2020 of French ccAFU guidelines - Editorial
    Mejean, A.
    Bensalah, K.
    Murez, T.
    Roupret, M.
    Rozet, F.
    PROGRES EN UROLOGIE, 2018, 28 (12): : S1 - S2
  • [7] Update 2018-2020 of French ccAFU guidelines - Editorial
    Mejean, A.
    Bensalah, K.
    Murez, T.
    Roupret, M.
    Rozet, F.
    PROGRES EN UROLOGIE, 2018, 28 : R3 - R4
  • [8] French ccAFU guidelines - Update 2018-2020: Management of kidney cancer
    Bensalah, K.
    Albiges, L.
    Bernhard, J. -C.
    Bigot, P.
    Bodin, T.
    Boissier, R.
    Correas, J. -M.
    Gimel, P.
    Hetet, J. -F.
    Long, J. -A.
    Nouhauda, F. -X., I
    Ouzdid, I.
    Rioux-Leclercq, N.
    Mejean, A.
    PROGRES EN UROLOGIE, 2018, 28 : R5 - R33
  • [9] French ccAFU guidelines - Update 2018-2020: Retroperitoneal sarcoma
    Murez, T.
    Savoie, P. -H.
    Flechon, A.
    Durand, X.
    Rocher, L.
    Camparo, P.
    Morel-Journel, N.
    Ferretti, L.
    Sebe, P.
    Mejean, A.
    PROGRES EN UROLOGIE, 2018, 28 : R167 - R176
  • [10] RETRACTED: French ccAFU guidelines - Update 2018-2020: Adrenal cancer (Retracted Article)
    Savoie, P-H
    Murez, T.
    Flechon, A.
    Sebe, P.
    Rocher, L.
    Camparo, P.
    Morel-Journel, N.
    Ferretti, L.
    Mejean, A.
    PROGRES EN UROLOGIE, 2018, 28 (12): : S175 - S193